The global market for Hepatits A Vaccine was valued to be USD 2.7 billion in 2022 to grew to USD 4.2 billion by 2031 with an expected rise at a CAGR of 4.8%. Over the projection period, the North America would lead the global regional market.
Rising government campaigns for immunization programs, greater awareness of preventative healthcare, and more travel to endemic areas are driving consistent expansion in the Hepatitis A vaccination market. Key drivers of market growth include the great effectiveness of the vaccination in avoiding Hepatitis A infection and its inclusion in regular children immunization programs in many nations. Furthermore, the creation of combination vaccinations shielding against many illnesses, including Hepatitis A, presents fresh prospects for industry operators.
Market Trends: Growing need for combo vaccinations providing immunity against many illnesses
Combining vaccinations that provide protection against many illnesses in one injection is a major trend driving change in the market for Hepatitis A. Convenience and cost-effectiveness of these combination vaccines—which provide protection against both Hepatitis A and B or Hepatitis A and typhoid—are driving their increasing popularity. By reducing the needed injection count, they increase patient compliance and streamline vaccination regimens. This tendency especially helps travelers needing many shots and in pediatric vaccinations. Research and development investments by manufacturers help to produce creative combination vaccines, which should propel market expansion and provide fresh chances for product differentiation.
Market Driver: Increasing government campaigns for immunizations
The expansion of the Hepatitis A vaccination market is mostly attributed to government projects and immunization campaigns. Particularly for children and high-risk populations, several nations have included Hepatitis A vaccine among their national immunization campaigns. These initiatives seeks to lower the illness load and related medical expenses. Governments and public health groups are also funding awareness programs to inform the people on the need of the Hepatitis A vaccine. Furthermore increasing availability to Hepatitis A vaccinations in areas with high illness frequency is financing for vaccine procurement and distribution in underdeveloped nations via groups such as GAVI (The Vaccine Alliance). These programs are greatly increasing vaccination rates and helping the industry to flourish.
Restraints in the Market: High cost of manufacture and research of vaccines
The Hepatitis A vaccine market is still much limited by the great expense involved in vaccine research and manufacture. New vaccine development calls for large expenditures in manufacturing facilities, research, and clinical testing. The complicated manufacturing process, with strict quality control standards and specialized tools, adds to the total cost. Higher vaccination costs resulting from these elements may restrict availability, particularly in low- and middle-income nations. Further adding to the expense load are the requirements for cold chain transit and storage. Furthermore discouraging some businesses from joining or growing in this field are the lengthy development times and legal obstacles involved in launching new vaccines to market. Particularly in resource-constrained environments, this cost barrier might impede attempts to reach general vaccination coverage and slow down market expansion.
Inactive Vaccine Rules the Market
Due to great effectiveness and safety profile, inactivated vaccines dominate the Hepatitis A vaccination industry. With the highest market share, the sector on inactivated vaccines dominates the Hepatitis A vaccination market. Dead virus particles included in inactivated vaccinations induce a robust immune response without running the danger of causing infection. High effectiveness rates of these vaccinations have shown long-lasting defense against Hepatitis A infection. Children, adults, and immunocompromised people among other demographics may find them appropriate based on their demonstrated safety profile and stability. The possibility of the inactivated vaccines to be mixed with different antigens in multivalent formulations increases their commercial attraction even further. Major pharmaceutical firms have made significant investments in the creation and manufacturing of inactivated Hepatitis A vaccines, therefore helping to explain their market dominance.
The Hepatitis A Vaccine Market Leader is North America
High awareness and strong healthcare infrastructure inspire regional supremacy. With the United States leading the main contribution, North America boasts the highest proportion of Hepatitis A vaccinations used worldwide. The area's supremacy may be ascribed to its strong government backing of vaccination programs, high knowledge of preventative healthcare, and solid healthcare system. Hepatitis A vaccinations included into regular children immunization programs and guidelines for high-risk adults have greatly increased vaccination rates. Major vaccine makers, cutting-edge research institutes, and attractive reimbursement rules also help the area to be industry leader. Growing attention on travel vaccinations and rising acceptance of combination vaccines could help to propel market expansion in North America over the next years.
Intense rivalry among a few big firms and numerous smaller regional producers defines the Hepatitis A vaccine industry. Important businesses are concentrating on research and development to launch novel goods like combination vaccinations and better formulations with more stability. Common tactics used to increase market presence and product offers include strategic alliances, mergers, and acquisitions. Manufacturers are also making investments in increasing their capacity for output to satisfy the rising demand worldwide. Particularly in underdeveloped countries, where cost-sensitive government bids are rather important in vaccine procurement, price competition is quite noteworthy. Companies are concentrating more and more on developing countries in order to meet the rising demand for Hepatitis A vaccinations there.
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Sanofi S.A.
- Pfizer Inc.
- Serum Institute of India Pvt. Ltd.
- Bharat Biotech
- Zydus Cadila
- Biological E Limited
- LG Chem
- Sinovac Biotech Ltd.
GlaxoSmithKline plc announced in 2023 the successful completion of Phase III clinical studies for their novel combination vaccination aiming at Hepatitis A and B viruses.
In particular, the FDA approval in 2022 for an extended indication of its Hepatitis A vaccination, Merck & Co., Inc. may now use its vaccination in those with certain immunocompromising illnesses.
1. INTRODUCTION
1.1. Market Definition
1.2. Study Scope
1.3. Currency Conversion
1.4. Study Period (2022- 2031)
1.5. Regional Coverage
2. RESEARCH METHODOLOGY
2.1. Primary Research
2.2. Secondary Research
2.3. Company Share Analysis
2.4. Data Triangulation
3. EXECUTIVE SUMMARY
3.1. Global Hepatitis A Vaccine Market (2018 – 2022)
3.2. Global Hepatitis A Vaccine Market (2023 – 2031)
3.2.1. Market Segment By Type (2023 – 2031)
3.2.2. Market Segment By Patient Type (2023 – 2031)
3.2.3. Market Segment By Distribution Channel (2023 – 2031)
4. MARKET DYNAMICS
4.1. Market Trends
4.1.1. Rising demand for combination vaccines offering protection against multiple diseases
4.1.2. Increasing focus on travel vaccines
4.1.3. Growing adoption of temperature-stable formulations
4.2. Market Drivers
4.2.1. Increasing government initiatives and immunization programs
4.2.2. Rising awareness about preventive healthcare
4.2.3. Expanding vaccination recommendations for high-risk groups
4.3. Market Restraints
4.3.1. High cost of vaccine development and production
4.3.2. Limited access in low-income countries
4.4. Porter's Five Forces Analysis
4.4.1. Threat of New Entrants
4.4.2. Bargaining Power of Buyers/Consumers
4.4.3. Bargaining Power of Suppliers
4.4.4. Threat of Substitute Products
4.4.5. Intensity of Competitive Rivalry
4.5. Supply Chain Analysis
4.6. Pricing Analysis
4.7. Regulatory Analysis
4.8. Pipeline Analysis
5. BY TYPE (MARKET VALUE (US$ MILLION) – 2022-2031*)
5.1. Inactivated Vaccine
5.2. Live Attenuated Vaccine
6. BY PATIENT TYPE
6.1. Adult
6.2. Pediatric
7. BY DISTRIBUTION CHANNEL
7.1. Hospital Pharmacies
7.2. Retail Pharmacies
7.3. Online Pharmacies
8. REGION
8.1. North America
8.1.1. United States
8.1.2. Canada
8.1.3. Mexico
8.2. South America
8.2.1. Brazil
8.2.2. Argentina
8.2.3. Rest of South America
8.3. Europe
8.3.1. Germany
8.3.2. United Kingdom
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Rest of Europe
8.4. Asia-Pacific
8.4.1. China
8.4.2. Japan
8.4.3. India
8.4.4. Australia
8.4.5. South Korea
8.4.6. Rest of Asia-Pacific
8.5. Middle-East
8.5.1. UAE
8.5.2. Saudi Arabia
8.5.3. Turkey
8.5.4. Rest of Middle East
8.6. Africa
8.6.1. South Africa
8.6.2. Egypt
8.6.3. Rest of Africa
9. COMPETITIVE LANDSCAPE
9.1. Key Developments
9.2. Company Market Share Analysis
9.3. Product Benchmarking
10. SWOT ANALYSIS
11. COMPANY PROFILES
11.1. GlaxoSmithKline plc
11.2. Merck & Co., Inc.
11.3. Sanofi S.A.
11.4. Pfizer Inc.
11.5. Serum Institute of India Pvt. Ltd.
11.6. Bharat Biotech
11.7. Zydus Cadila
11.8. Biological E Limited
11.9. LG Chem
11.10. Sinovac Biotech Ltd.
11.11. AstraZeneca plc
11.12. CSL Limited (*LIST NOT EXHAUSTIVE)
12. MARKET OPPORTUNITIES
By Type:
By Patient Type:
By Distribution Channel:
By Region:
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511
